Summer is upon us. Or so I hear from news reports of heat waves and thunderstorms. Living in San Diego, we don't have summer, nor winter, nor fall. Venture capital investing, on the other hand, isn't nearly as hot. After the first quarter of 2012 that was a wildfire relative to 2011, the second quarter didn't keep pace and saw us slip below 2011 levels. Read More
Shares in Diamyd Medical AB dropped 30 percent Tuesday on news that its gene therapy treatment for cancer pain missed the primary endpoint in a Phase II placebo-controlled trial. Read More
Later this month, the International AIDS Conference is set to occur on U.S. soil for the first time in more than two decades, and researchers have high hopes for the meeting, whose theme is "Turning the Tide Together." Read More
GlobeImmune Inc. filed for a $69 million initial public offering (IPO) to advance its cancer and infectious disease products developed using the Tarmogen platform. Read More
• CorMedix Inc., of Bridgewater, N.J., said the NYSE-Amex accepted its plan to regain compliance with continued listing standards and granted the company an extension to Aug. 22 to meet the standards. Read More
• Spectrum Pharmaceuticals Inc., of Henderson, Nev., said it started a Phase II trial of lucanthrone, an orally administered topoisomerase II and AP endonuclease inhibitor, as a primary therapy for glioblastoma multiforme. Read More
• Mundipharma International Ltd., of Cambridge, UK, said the European Commission approved combination therapy flutiform (fluticasone propionate/formoterol fumarate) for the maintenance treatment of asthma. Read More
